<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368663</url>
  </required_header>
  <id_info>
    <org_study_id>TJ-134</org_study_id>
    <nct_id>NCT04368663</nct_id>
  </id_info>
  <brief_title>The Beneficial Effect of TJ-134 for Patients With Symptomatic Pneumatosis Cystoides Intestinalis</brief_title>
  <official_title>The Beneficial Effect of the Traditional Japanese Medicine, Keishi-ka-shakuyaku-daio-to（TJ-134）for Patients With Symptomatic Pneumatosis Cystoides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Showa Inan General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Showa Inan General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to is administered to patients
      with symptomatic pneumatosis cystoides intestinalis (PCI) as compared with lactomin for 8
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Based on endoscopic finding, patients with symptomatic PCI are recruited.

        2. After enrollment, abdominal symptoms are evaluated and abdominal CT is performed.

        3. Patients were randomized in a 1:1 ratio in blocks of 4 to undergo either the traditional
           Japanese medicine or lactomin (control). Randomization was carried out by
           computer-generated random sequences.

        4. The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to（TJ-134, 7.5g/day), which
           consists of a mixture of a compound of peony root (6 g), cinnamon bark (4 g), jujube (4
           g), glycyrrhiza (2 g), rhubarb (2 g), and ginger (1 g) or lactomin (3g/day) is
           administered to enrolled patients for 8 weeks.

        5. After the administration of each drug for 8 weeks, abdominal symptoms are evaluated and
           abdominal CT is performed again.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of computed tomography (CT) findings</measure>
    <time_frame>at enrollment and 8 weeks after the administration of TJ134</time_frame>
    <description>Change of the intraluminal gas pockets in the colon on CT images before and after the administration of TJ-134</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bloating and abdominal pain</measure>
    <time_frame>at enrollment and 8 weeks after the administration of TJ134</time_frame>
    <description>Both bloating and abdominal pain are evaluated using visual analogue scale (VAS) score (0-100; 0, none).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal symptoms</measure>
    <time_frame>at enrollment and 8 weeks after the administration of TJ134</time_frame>
    <description>Abdominal symptoms were evaluated on the Gastrointestinal Symptoms Rating Scale (GSRS) one a scale of 1 to5 (1 = none).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pneumatosis Cystoides Intestinalis</condition>
  <arm_group>
    <arm_group_label>TJ-134 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to（TJ-134, 7.5g/day), which consists of a mixture of a compound of peony root (6 g), cinnamon bark (4 g), jujube (4 g), glycyrrhiza (2 g), rhubarb (2 g), and ginger (1 g) is administered to enrolled patients for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactomin group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactomin (3g/day) is administered to enrolled patients for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Japanese traditional medicine group</intervention_name>
    <description>TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.</description>
    <arm_group_label>Lactomin group</arm_group_label>
    <arm_group_label>TJ-134 group</arm_group_label>
    <other_name>Lactomin group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  typical findings of PCI on colonoscopy; Line or pebble like sessile cysts are
             distributed around the colon with normal overlying mucosa

        Exclusion Criteria:

          -  patients can not take Keishi-ka-shakuyaku-daio-to（TJ-134）
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Showa Inan General hospital</name>
      <address>
        <city>Komagane</city>
        <state>Nagano</state>
        <zip>399-4117</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Horiuchi, M.D.</last_name>
      <phone>81265822121</phone>
      <phone_ext>3012</phone_ext>
      <email>horiuchi.akira@sihp.jp</email>
    </contact>
    <investigator>
      <last_name>Akira Horiuchi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Showa Inan General Hospital</investigator_affiliation>
    <investigator_full_name>Akira Horiuchi</investigator_full_name>
    <investigator_title>Chief of Digestive Disease Center</investigator_title>
  </responsible_party>
  <keyword>Pneumatosis Cystoides Intestinalis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumatosis Cystoides Intestinalis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

